Show simple item record

dc.contributor.authorLee, Shannon
dc.contributor.authorRauch, Jens
dc.contributor.authorKolch, Walter
dc.date.accessioned2020-09-24T09:54:44Z
dc.date.available2020-09-24T09:54:44Z
dc.date.issued2020-02-07
dc.identifier.pmid32046099
dc.identifier.doi10.3390/ijms21031102
dc.identifier.urihttp://hdl.handle.net/10147/628333
dc.descriptionMitogen-activated protein kinase (MAPK) pathways represent ubiquitous signal transduction pathways that regulate all aspects of life and are frequently altered in disease. Here, we focus on the role of MAPK pathways in modulating drug sensitivity and resistance in cancer. We briefly discuss new findings in the extracellular signaling-regulated kinase (ERK) pathway, but mainly focus on the mechanisms how stress activated MAPK pathways, such as p38 MAPK and the Jun N-terminal kinases (JNK), impact the response of cancer cells to chemotherapies and targeted therapies. In this context, we also discuss the role of metabolic and epigenetic aberrations and new therapeutic opportunities arising from these changes.en_US
dc.language.isoenen_US
dc.subjectERKen_US
dc.subjectJNKen_US
dc.subjectMAPKen_US
dc.subjectCANCERen_US
dc.subjectcombination therapyen_US
dc.subjectdrug resistanceen_US
dc.subjectepigeneticsen_US
dc.subjectmetabolismen_US
dc.subjectp38en_US
dc.titleTargeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity.en_US
dc.typeArticleen_US
dc.typeOtheren_US
dc.identifier.eissn1422-0067
dc.identifier.journalInternational journal of molecular sciencesen_US
dc.source.journaltitleInternational journal of molecular sciences
dc.source.volume21
dc.source.issue3
refterms.dateFOA2020-09-24T09:54:45Z
dc.source.countryIreland
dc.source.countryIreland
dc.source.countrySwitzerland


Files in this item

Thumbnail
Name:
ijms-21-01102-v2.pdf
Size:
1.774Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record